Investor Presentaiton

Future Outlook: Pipeline Products Pending Approval in Near Future will be a Key Driver for Future Sales Growth Gene therapy & gene editing B-Vec (HSV-1) Krystal Bio Upstaza (AAV) PTC Therapeutics Fidanacogene elaparvovec (AAV) SRP-9001 (AAV) Sarepta Therapeutics Roctavian (AAV) BioMarin Pfizer CTX-001 (ex vivo CRISPR/Cas) CRISPR & Vertex Lumevoq (AAV) GenSight bb1111 (lentivirus) Bluebird Bio EtranaDez* (AAV) uniQure & CSL Behring Cell therapy Omidubicel (allogenic HSC) Gamida Cell ACE-02 (autologous epidermis) J-TEC Lantidra (pancreatic islet cells) CellTrans NurOwn (MSC) BrainStorm Lifileucel (TIL) lovance Tab-Cel (allogeneic T-cell) Atara Bio Libmeldy (autologous HSC) Orchard Therapeutics HPC cord blood (UCB HPC) StemCyte SB623 (MSC) Sumitomo Pharma Afami-cel (TCR-T) Adaptimmune Therapeutics. CT-053 (CAR-T) CARsgen Therapeutics Inaticabtagene autoleucel (CAR-T) Juventas Legend Note: *Approved by FDA in 2022 under the name of Hemgenix; pending EU approval Source: The Alliance for Regenerative Medicine, public information Approved by FDA in 2023 Pending approval 老药明康德 Wuxi AppTec

View entire presentation